The radiation sensitizer Misonidazole (MISO) can selectively potentiate the effectiveness of certain conventional chemotherapeutic agents in vitro and in vivo. In virtually every system tested, the enhancement of tumor toxicity has exceeded any concommitant increase in normal tissue damage. In order to accurately evaluate the potential of this therapy and to exploit it to the fullest, it is necessary to establish underlying mechanisms. One long term objective of this proposal is to examine the mechanisms of chemopotentiation when cells are incubated with MISO after treatment with nitrosoureas. The extent and kinetics of DNA cross-link formation after treatment will be assessed in EMT-6 cells and two human cell lines, IMR-90 and VA-13. The latter cell line is deficient (Mer-) in alklytransferase activity and inefficient at excising chloroethyl monoadducts from DNA after nitrosourea treatment, while the former demonstrates this ability (Mer+). The role of alkyltransferase activity in chemopotentiation by MISO will be examined. Glutathione (GSH) depletion will also be monitored. Both effects will be compared to the magnitude of chemopotentiation and the loss of chemopotentiation when post-incubation with MISO is delayed after nitrosourea treatment. The second long term objective of the proposed research is to synthesize improved chemopotentiating agents based on our previous structure-activity investigations. Specifically, experiments will be designed to test the hypothesis that the addition of a side chain, capable of generating an isocyanate, to a nitrogen heterocycle can improve chemopotentiating activity. In preliminary experiments this approach has proven very promising. Synthetic efforts will attempt to define specific structural parameters influencing the chemosensitizing, radiosensitizing, and cytotoxic properties of isocyanate-generating nitroheterocyles in vitro and in vivo.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA042325-02
Application #
3183446
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1985-08-01
Project End
1990-03-31
Budget Start
1986-04-01
Budget End
1987-03-31
Support Year
2
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Borch, R F; Liu, J; Schmidt, J P et al. (2000) Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agents. J Med Chem 43:2258-65
Beall, H D; Mulcahy, R T; Siegel, D et al. (1994) Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases. Cancer Res 54:3196-201
Mulcahy, R T; Gipp, J J; Schmidt, J P et al. (1994) Nitrobenzyl phosphorodiamidates as potential hypoxia-selective alkylating agents. J Med Chem 37:1610-5
Chan, K K; Hong, P S; Tutsch, K et al. (1994) Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508. Cancer Res 54:6421-9
Ross, D; Siegel, D; Beall, H et al. (1993) DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C. Cancer Metastasis Rev 12:83-101
Bailey, H; Mulcahy, R T; Tutsch, K D et al. (1991) A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection. Cancer Res 51:1099-104
Gipp, J J; McClelland, R A; Mulcahy, R T (1991) DNA damage induced in HT-29 colon cancer cells by exposure to 1-methyl-2-nitrosoimidazole, a reductive metabolite of 1-methyl-2-nitroimidazole. Biochem Pharmacol 42 Suppl:S127-33
Firestone, A; Mulcahy, R T; Borch, R F (1991) Nitroheterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells. J Med Chem 34:2933-5
Ublacker, G A; Johnson, J A; Siegel, F L et al. (1991) Influence of glutathione S-transferases on cellular glutathione determination by flow cytometry using monochlorobimane. Cancer Res 51:1783-8
Mulcahy, R T; Gipp, J J; Ublacker, G A et al. (1990) Enhancement of melphalan (L-PAM) toxicity by reductive metabolites of 1-methyl-2-nitroimidazole, a model nitroimidazole chemosensitizing agent. Biochem Pharmacol 40:2671-6

Showing the most recent 10 out of 18 publications